MS: Busting the Myths
June 14, 2021 | Advocacy, Treatments, Trials
About 10% of people with MS are diagnosed with Primary Progressive Multiple Sclerosis (PPMS). While more common forms of MS involve a relapse-remit pattern (unpredictable attacks followed by periods of disease inactivity), PPMS is characterised by a slow onset and […]
June 8, 2021 | Advocacy, Media
Multiple Sclerosis NZ is thrilled to announce our President, Neil Woodhams, has received an honour in the Queen’s Birthday List for recognition of his services to people with Multiple Sclerosis. Neil is a leading advocate for New Zealanders with MS, […]
June 3, 2021 | Advocacy, Covid-19, Event, Treatments, Uncategorised
Understandably, there is a high level of interest within the Multiple Sclerosis (MS) Community for information about how the Pfizer vaccine works and is impacting people with MS globally. Due to this Multiple Sclerosis New Zealand and the Ministry of […]
May 26, 2021 | Advocacy
Multiple Sclerosis NZ received several reports from concerned patients regarding the ambiguity of the Special Authority Criteria for DMTs. With the support of Dr John Mottershead, Pharmac were approached for clarification. Concern centred around whether bilateral aids qualify for use […]
May 25, 2021 | Advocacy, Media
Still unfunded, but finally acknowledged, McDonald 2017 criteria for diagnosing Multiple Sclerosis (MS) is one step closer to being used in NZ for accessing treatment. The February 2021 minutes of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) were released this month, recommending […]